Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.290
+0.070 (1.66%)
At close: Mar 9, 2026, 4:00 PM EDT
4.250
-0.040 (-0.93%)
After-hours: Mar 9, 2026, 7:03 PM EDT
Aquestive Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 44.55 | 57.56 | 50.58 | 47.68 | 50.83 | |
| Revenue Growth (YoY) | -22.61% | 13.79% | 6.09% | -6.20% | 10.87% | |
| Cost of Revenue | 18.56 | 17.87 | 20.83 | 19.39 | 14.99 | |
| Gross Profit | 25.99 | 39.69 | 29.75 | 28.29 | 35.84 | |
| Selling, General & Admin | 79.85 | 50.18 | 31.75 | 52.88 | 53.48 | |
| Research & Development | 17.19 | 20.28 | 13.1 | 17.48 | 17.05 | |
| Operating Expenses | 97.04 | 70.46 | 44.85 | 70.36 | 70.52 | |
| Operating Income | -71.05 | -30.77 | -15.1 | -42.07 | -34.68 | |
| Interest Expense | -17.1 | -16.82 | -7.46 | -12.44 | -22.46 | |
| Interest & Investment Income | 4.37 | 3.14 | 1.82 | 0.1 | 0.42 | |
| Other Non Operating Income (Expenses) | - | - | 6 | - | - | |
| EBT Excluding Unusual Items | -83.78 | -44.45 | -14.74 | -54.41 | -56.72 | |
| Legal Settlements | - | - | 8.5 | - | - | |
| Other Unusual Items | - | 0.3 | -1.38 | - | -13.82 | |
| Pretax Income | -83.78 | -44.15 | -7.63 | -54.41 | -70.54 | |
| Income Tax Expense | - | -0.01 | 0.25 | - | - | |
| Net Income | -83.78 | -44.14 | -7.87 | -54.41 | -70.54 | |
| Net Income to Common | -83.78 | -44.14 | -7.87 | -54.41 | -70.54 | |
| Shares Outstanding (Basic) | 107 | 87 | 61 | 49 | 38 | |
| Shares Outstanding (Diluted) | 107 | 87 | 61 | 49 | 38 | |
| Shares Change (YoY) | 23.29% | 41.58% | 25.69% | 27.99% | 13.15% | |
| EPS (Basic) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 | |
| EPS (Diluted) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 | |
| Free Cash Flow | -52.99 | -35.92 | -7.38 | -10.84 | -33.89 | |
| Free Cash Flow Per Share | -0.50 | -0.41 | -0.12 | -0.22 | -0.89 | |
| Gross Margin | 58.34% | 68.95% | 58.82% | 59.34% | 70.51% | |
| Operating Margin | -159.50% | -53.46% | -29.86% | -88.23% | -68.22% | |
| Profit Margin | -188.09% | -76.68% | -15.56% | -114.12% | -138.77% | |
| Free Cash Flow Margin | -118.97% | -62.40% | -14.58% | -22.74% | -66.67% | |
| EBITDA | -70.48 | -30.03 | -13.73 | -39.51 | -31.53 | |
| EBITDA Margin | -158.22% | -52.17% | -27.14% | -82.87% | -62.02% | |
| D&A For EBITDA | 0.57 | 0.74 | 1.37 | 2.55 | 3.15 | |
| EBIT | -71.05 | -30.77 | -15.1 | -42.07 | -34.68 | |
| EBIT Margin | -159.50% | -53.46% | -29.86% | -88.23% | -68.22% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.